A systems biology approach to characterize the regulatory networks leading to trabectedin resistance in an in vitro model of myxoid liposarcoma.
Trabectedin, a new antitumor compound originally derived from a marine tunicate, is clinically effective in soft tissue sarcoma. The drug has shown a high selectivity for myxoid liposarcoma, characterized by the translocation t(12;16)(q13; p11) leading to the expression of FUS-CHOP fusion gene. Trab...
Main Authors: | Sarah Uboldi, Enrica Calura, Luca Beltrame, Ilaria Fuso Nerini, Sergio Marchini, Duccio Cavalieri, Eugenio Erba, Giovanna Chiorino, Paola Ostano, Daniela D'Angelo, Maurizio D'Incalci, Chiara Romualdi |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3327679?pdf=render |
Similar Items
-
Eribulin Provides a Remarkable Effect in Trabectedin-Resistant Myxoid Liposarcoma
by: Hironari Tamiya, et al.
Published: (2020-01-01) -
Tumor Calcification: A New Response Pattern of Myxoid Liposarcoma to Trabectedin
by: Anthony Turpin, et al.
Published: (2014-03-01) -
Trabectedin as second-line treatment in metastatic myxoid liposarcoma: a case report
by: Pedrinaci Irene Zarcos, et al.
Published: (2012-12-01) -
Vulvar Myxoid Liposarcoma
by: Tzong-Cheng Wu, et al.
Published: (2007-09-01) -
Trabectedin and Plitidepsin: Drugs from the Sea that Strike the Tumor Microenvironment
by: Carlos M. Galmarini, et al.
Published: (2014-01-01)